Abstract
The hyperphosphatemia is common in hemodialysis patients and it is important in the development of bone mineral disease. It contributes to soft tissue calcification, raising the risk of cardiovascular diseases and mortality. Removal by dialysis, reduction of the intestinal absorption through phosphate binder and intake reduction of phosphorus are the main therapeutic strategies for the co…